We compared the SUVmax between the PD-L1-positive and the PD-L1-negative group observed significant differences among NSCLC (13.55 ± 7.23 vs. 8.22 ± 5.77; p < 0.0001), ADC (10.89 ± 6.05 vs. 7.21 ± 5.15; p < 0.0001), and SCC (17.41 ± 7.42 vs. 14.25 ± 4.85; p=0.006) patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.